Chester County News and Community Website
YARDLEY, PA — Jubilant Therapeutics reported early clinical activity for JBI-802 in a Phase 1/2 trial of patients with myeloproliferative neoplasms, with dose-responsive platelet reductions observed across several disease subtypes …
Jubilant Reports Early Platelet Reductions With JBI-802 Read More
PLYMOUTH MEETING, PA — Adverse-event reports for Braeburn’s Brixadi remained low and relatively stable during its first 18 months on the U.S. market, according to a company-funded study examining federal …
Braeburn Study Finds Low Adverse-Event Reporting for Brixadi Read More
WEST CHESTER, PA — Chester County health inspectors cited restaurants and other food facilities for improper food temperatures, cross-contamination risks, sanitation deficiencies and pest-related concerns during inspections conducted Sept. 21, …
Dead Roaches, Fruit Flies Among Chester County Inspection Findings Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network is funding four quality-improvement projects aimed at reducing gaps in metastatic prostate cancer care, targeting disparities in access, inconsistent testing and …
NCCN Funds Projects to Close Gaps in Prostate Cancer Care Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Fayuvi, a one-time gene therapy from Ultragenyx Pharmaceutical Inc., as the first treatment for children with mucopolysaccharidosis type IIIA, providing …
FDA Approves First Treatment for Sanfilippo Syndrome Type A Read More
WASHINGTON, D.C. — The Centers for Medicare & Medicaid Services will expand its outcome-based ACCESS payment model in spring 2027 to cover heart failure, chronic obstructive pulmonary disease, substance use …
CMS Expands Outcome-Based Medicare Care to More Conditions Read More
WASHINGTON, D.C. — The Advanced Research Projects Agency for Health launched SPECTRA on Sept. 17, a federal research program designed to combine biological, clinical, and behavioral data with computational tools …
ARPA-H Launches Autism Program to Push Precision Care Read More
WILMINGTON, DE — AstraZeneca (NYSE: AZN) and Daiichi Sankyo’s Enhertu extended median progression-free survival by six months versus pembrolizumab plus chemotherapy in a Phase III trial of first-line treatment for …
Enhertu Extends PFS by Six Months in HER2 Lung Cancer Read More
BIRMINGHAM, AL — The U.S. Department of Health and Human Services awarded nearly $25 million to 132 small rural hospitals across 13 states on Sept. 10, directing federal funding toward …
HHS Directs Nearly $25 Million to 132 Rural Hospitals Read More WILMINGTON, DE — AstraZeneca’s (NYSE: AZN) Tagrisso showed a sustained survival benefit eight years after treatment in a Phase III trial of patients with early-stage EGFR-mutated non-small cell lung cancer, …
Tagrisso Cuts Death Risk 47% in Long-Term Lung Cancer Trial Read More